Organon & Co | OGN - Ordinary Share Capital


Organon & Co reported $262.65M in Ordinary Share Capital for its fiscal quarter ending in March of 2026.





Ordinary Share Capital Change Date
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Celltrion KRW 229.65M 11.03M Mar/2026
Cspc Pharmaceutical CNY 11.52B 3.7M Dec/2025
Deva Holding AS TRY 200.02M 0 Sep/2023
Dianthus Therapeutics USD 54.58M 11.36M Mar/2026
Divis Laboratories Ltd INR 265.47M 0 Mar/2026
Gilead Sciences USD 1.24B 1000K Mar/2026
Glaxosmithkline GBP 4.05B 20.6M Mar/2026
Kangmei Pharma CNY 13.83B 0 Mar/2026
Knight Therapeutics CAD 99.68M 24.66K Sep/2025
Laboratorios Farma EUR 51.82M 1.55M Dec/2023
Malin Corporation EUR 200K 0 Dec/2024
Medical Developments International AUD 112.66M 2.35M Dec/2025
Merck USD 2.47B 12.72M Dec/2025
Neuren Pharmaceuticals AUD 126.64M 38.63M Dec/2025
Novartis USD 1.91B 60K Mar/2026
Organigram Holdings CAD 136.47M 1.34M Mar/2026
Organon & Co USD 262.65M 2.33M Mar/2026
Ovoca Bio EUR 29.49M 18.43M Jun/2025
Pharma Mar EUR 17.36M 0 Mar/2026
Qiagen NV USD 216.56M 284.67K Dec/2025
Sartorius EUR 69.05M 0 Mar/2026
Sino Biopharmaceutical CNY 17.89B 30.5M Jun/2025
Tilray USD 116.52M 5.01M Sep/2025
Zealand Pharma A/S 70.61M 319.68K Dec/2025